In a fast changing world some nation stands as one of the future leading country and renowned for its agricultural and dairy industry. Preponderance of global economy based on livestock industry with global climatic changes many times it faces huge losses being incurred by the loss of grazing, diseases, deaths of animals. So it is undeniable requirement to develop newer antimicrobials to fight against bacterial infections. Fluoroquinolones are the fastest growing antibacterial class in terms of global revenue, increasingly being used in both the hospital and community sectors to treat a broad range of infections. Moxifloxacin is a latest fourth generation fluoroquinolone having 8 - methoxy - quinolone ring and bulky C7 side chain with broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, anaerobes and atypical organisms such as Mycoplasma spp. and Chlamydia spp. Resistance to microorganisms is less with moxifloxacin because it is bactericidal, and also have low MIC values, extended spectrum activity, less chances of toxicity and adverse drug reaction, moxifloxacin is very promising antibiotics for its use in human and veterinary medicine.